TherapeuticsMD (TXMD) Rating Reiterated by Oppenheimer

TherapeuticsMD (NASDAQ:TXMD)‘s stock had its “buy” rating reissued by research analysts at Oppenheimer in a report issued on Wednesday.

Several other equities analysts have also issued reports on the company. Noble Financial reaffirmed a “buy” rating on shares of TherapeuticsMD in a report on Thursday, November 30th. BidaskClub lowered TherapeuticsMD from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 31st. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $31.00 target price on shares of TherapeuticsMD in a report on Wednesday, November 29th. Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Saturday, January 20th. Finally, Deutsche Bank set a $9.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a report on Wednesday, December 20th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $14.50.

TXMD stock opened at $5.10 on Wednesday. TherapeuticsMD has a twelve month low of $3.50 and a twelve month high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Tuesday, February 20th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The business had revenue of $4.13 million during the quarter, compared to the consensus estimate of $4.66 million. TherapeuticsMD had a negative net margin of 458.49% and a negative return on equity of 63.67%. The business’s revenue was down 8.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.12) earnings per share. research analysts forecast that TherapeuticsMD will post -0.38 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in TXMD. MANA Advisors LLC bought a new position in TherapeuticsMD during the fourth quarter valued at $104,000. Paloma Partners Management Co bought a new position in TherapeuticsMD during the fourth quarter valued at $105,000. Edge Wealth Management LLC lifted its position in shares of TherapeuticsMD by 2,500.0% during the fourth quarter. Edge Wealth Management LLC now owns 20,800 shares of the company’s stock worth $125,000 after acquiring an additional 20,000 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of TherapeuticsMD during the third quarter worth $189,000. Finally, Claraphi Advisory Network LLC purchased a new stake in shares of TherapeuticsMD during the fourth quarter worth $275,000. 73.27% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “TherapeuticsMD (TXMD) Rating Reiterated by Oppenheimer” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with's FREE daily email newsletter.

Leave a Reply